BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 29900892)

  • 21. Twenty five years follow up of MB leprosy patients retreated with a modified MDT regimen after a full course of dapsone mono-therapy.
    Jing Z; Zhang R; Zhou D; Chen J
    Lepr Rev; 2009 Jun; 80(2):170-6. PubMed ID: 19743621
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multidrug therapy in leprosy.
    Manglani PR; Arif MA
    J Indian Med Assoc; 2006 Dec; 104(12):686-8. PubMed ID: 17474286
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dapsone drug resistance in the MDT era.
    Roche PW; Neupane KD; Failbus SS; Butlin CR
    Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):323-5. PubMed ID: 11221097
    [No Abstract]   [Full Text] [Related]  

  • 24. Methemoglobinemia and dapsone levels in patients with leprosy.
    Vieira JL; Riveira JG; Martins Ade N; Silva JP; Salgado CG
    Braz J Infect Dis; 2010; 14(3):319-21. PubMed ID: 20835521
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of clofazimine and dapsone on rifampicin (Lositril) pharmacokinetics in multibacillary and paucibacillary leprosy cases.
    Mehta J; Gandhi IS; Sane SB; Wamburkar MN
    Indian J Lepr; 1985; 57(2):297-310. PubMed ID: 4078356
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone.
    Sapkota BR; Shrestha K; Pandey B; Walker SL
    Lepr Rev; 2008 Dec; 79(4):425-8. PubMed ID: 19274989
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Six years' follow-up of multibacillary leprosy patients treated with uniform multi-drug therapy in China.
    Shen J; Yan L; Yu M; Li J; Yu X; Zhang G
    Int J Dermatol; 2015 Mar; 54(3):315-8. PubMed ID: 25265933
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relapse study in smear positive multibacillary (MB) leprosy after 1 year WHO-multi-drug therapy (MDT) in Cebu, Philippines.
    Maghanoy A; Mallari I; Balagon M; Saunderson P
    Lepr Rev; 2011 Mar; 82(1):65-9. PubMed ID: 21644473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hemolytic anemia in patients receiving daily dapsone for the treatment of leprosy.
    Deps P; Guerra P; Nasser S; Simon M
    Lepr Rev; 2012 Sep; 83(3):305-7. PubMed ID: 23356031
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of multibacillary leprosy with a regimen of 13 weeks duration.
    Pattyn SR; Groenen G; Janssens L; Kuykens L; Mputu LB
    Lepr Rev; 1992 Mar; 63(1):41-6. PubMed ID: 1569815
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ambulatory treatment of multibacillary leprosy with a regimen of 8 months duration.
    Pattyn SR; Bourland J; Kazeze
    Lepr Rev; 1992 Mar; 63(1):36-40. PubMed ID: 1569814
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Longitudinal ocular survey of 202 Filipino patients with multi-bacillary (MB) leprosy treated with 2 year WHO-multiple drug therapy.
    Ravanes JM; Cellona RV; Balagon M; Abalos RM; Walsh GP; Walsh DS
    Southeast Asian J Trop Med Public Health; 2011 Mar; 42(2):323-30. PubMed ID: 21710853
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of leprosy.
    Kar HK; Gupta R
    Clin Dermatol; 2015; 33(1):55-65. PubMed ID: 25432811
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of corticosteroids usage on bacterial killing, clearance and nerve damage in leprosy; part 3--Study of two comparable groups of 100 multibacillary (MB) patients each, treated with MDT + steroids vs. MDT alone, assessed at 6 months post-release from 12 months MDT.
    Shetty VP; Khambati FA; Ghate SD; Capadia GD; Pai VV; Ganapati R
    Lepr Rev; 2010 Mar; 81(1):41-58. PubMed ID: 20496569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of a new fixed duration (12 weeks) multi-drug regimen of bactericidal drugs in multibacillary leprosy.
    Tejasvi T; Khaitan BK; Khanna N; Pandhi RK; Singh MK
    Indian J Lepr; 2006; 78(4):329-37. PubMed ID: 17402345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relapse as histoid leprosy after receiving multidrug therapy (MDT); a report of three cases.
    Shaw IN; Ebenezer G; Rao GS; Natrajan MM; Balasundaram B
    Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):272-6. PubMed ID: 11221089
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Leprosy in transplant recipients: report of a case after liver transplantation and review of the literature.
    Trindade MA; Palermo ML; Pagliari C; Valente N; Naafs B; Massarollo PC; D'Albuquerque LA; Benard G
    Transpl Infect Dis; 2011 Feb; 13(1):63-9. PubMed ID: 20678090
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relapse with multibacillary leprosy caused by rifampicin sensitive organisms following paucibacillary multidrug therapy.
    Soares DJ; Neupane K; Britton WJ
    Lepr Rev; 1995 Sep; 66(3):210-3. PubMed ID: 7500815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adverse effects from multi-drug therapy in leprosy: a Brazilian study.
    Deps PD; Nasser S; Guerra P; Simon M; Birshner Rde C; Rodrigues LC
    Lepr Rev; 2007 Sep; 78(3):216-22. PubMed ID: 18035772
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolism and interactions of antileprosy drugs.
    George J
    Biochem Pharmacol; 2020 Jul; 177():113993. PubMed ID: 32339493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.